ATE505203T1 - Pharmazeutische kombination aus aliskiren und valsartan - Google Patents

Pharmazeutische kombination aus aliskiren und valsartan

Info

Publication number: ATE505203T1
Authority: AT; Austria
Prior art keywords: aliskiren; valsartan; minutes; dose combination; fixed dose
Prior art date: 2007-09-28

Application number

AT08835893T

Other languages

English (en)

Inventor

Catherine Curdy

Shoufeng Li

Dieter Becker

Burkhard Schluetermann

Frederic Gerber

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-28

Filing date

2008-09-24

Publication date

2011-04-15

2008-09-24 Application filed by Novartis Ag filed Critical Novartis Ag

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE505203T1 publication Critical patent/ATE505203T1/de

Links

UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 title abstract 3
239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 3
229960004601 aliskiren Drugs 0.000 title abstract 3
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 3
229960004699 valsartan Drugs 0.000 title abstract 3
229940000425 combination drug Drugs 0.000 abstract 3
238000004090 dissolution Methods 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
238000000338 in vitro Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Rheumatology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT08835893T 2007-09-28 2008-09-24 Pharmazeutische kombination aus aliskiren und valsartan ATE505203T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97590507P	2007-09-28	2007-09-28
PCT/US2008/077417 WO2009045796A1 (en)	2007-09-28	2008-09-24	Pharmaceutical combination of aliskiren and valsartan

Publications (1)

Publication Number	Publication Date
ATE505203T1 true ATE505203T1 (de)	2011-04-15

Family

ID=40394241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08835893T ATE505203T1 (de)	2007-09-28	2008-09-24	Pharmazeutische kombination aus aliskiren und valsartan

Country Status (16)

Country	Link
US (1)	US20100247645A1 (de)
EP (1)	EP2205279B1 (de)
JP (1)	JP2010540548A (de)
KR (1)	KR20100059912A (de)
CN (1)	CN101808665A (de)
AT (1)	ATE505203T1 (de)
AU (1)	AU2008309059A1 (de)
BR (1)	BRPI0817275A2 (de)
CA (1)	CA2697437A1 (de)
DE (1)	DE602008006243D1 (de)
ES (1)	ES2364538T3 (de)
MX (1)	MX2010003439A (de)
PL (1)	PL2205279T3 (de)
PT (1)	PT2205279E (de)
RU (1)	RU2010116526A (de)
WO (1)	WO2009045796A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110287100A1 (en) *	2009-01-28	2011-11-24	Sabine Desset-Brethes	Galenic Formulations of Organic Compounds
EP2408427A1 (de) *	2009-03-20	2012-01-25	Novartis AG	Galenische formulierungen einer fixen dosiskombination aus valsartan und aliskiren
AR080683A1 (es) *	2010-03-16	2012-05-02	Novartis Ag	Composiciones farmaceuticas de aliskiren y metodos de administracion
SG174658A1 (en) *	2010-04-01	2011-10-28	Theravida Inc	Pharmaceutical formulations for the treatment of overactive bladder
US8940763B2 (en)	2011-05-10	2015-01-27	Theravida, Inc.	Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
CN102247344A (zh) *	2011-05-30	2011-11-23	北京阜康仁生物制药科技有限公司	一种新型降血压组合物
CN102626395B (zh) *	2012-04-19	2014-02-26	海南美兰史克制药有限公司	一种阿利克仑缬沙坦药物组合物脂质体固体制剂
ES2802252T3 (es) *	2012-05-01	2021-01-18	Althera Life Sciences Llc	Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
WO2013166114A1 (en) *	2012-05-01	2013-11-07	Althera Life Sciences, Llc	Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
US10376470B2 (en) *	2012-05-01	2019-08-13	Althera Life Sciences, Llc	Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
CN108697688A (zh)	2016-01-20	2018-10-23	塞拉维达公司	用于治疗多汗症的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
PE20142101A1 (es) *	2004-03-17	2014-12-27	Novartis Ag	Composiciones farmaceuticas de aliskiren
ES2384637T3 (es) *	2004-10-08	2012-07-10	Novartis Ag	Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica
US20100240760A1 (en) *	2005-03-22	2010-09-23	Jessie Gu	Biomarkers for Efficacy of Aliskiren as a Hypertensive Agent
CA2613417C (en) *	2005-06-27	2011-11-29	Daiichi Sankyo Company, Limited	Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker

2008
- 2008-09-24 PT PT08835893T patent/PT2205279E/pt unknown
- 2008-09-24 AT AT08835893T patent/ATE505203T1/de active
- 2008-09-24 US US12/679,052 patent/US20100247645A1/en not_active Abandoned
- 2008-09-24 BR BRPI0817275-7A patent/BRPI0817275A2/pt not_active IP Right Cessation
- 2008-09-24 CN CN200880108475A patent/CN101808665A/zh active Pending
- 2008-09-24 CA CA2697437A patent/CA2697437A1/en not_active Abandoned
- 2008-09-24 AU AU2008309059A patent/AU2008309059A1/en not_active Abandoned
- 2008-09-24 PL PL08835893T patent/PL2205279T3/pl unknown
- 2008-09-24 WO PCT/US2008/077417 patent/WO2009045796A1/en not_active Ceased
- 2008-09-24 ES ES08835893T patent/ES2364538T3/es active Active
- 2008-09-24 DE DE602008006243T patent/DE602008006243D1/de active Active
- 2008-09-24 RU RU2010116526/15A patent/RU2010116526A/ru not_active Application Discontinuation
- 2008-09-24 JP JP2010527092A patent/JP2010540548A/ja active Pending
- 2008-09-24 KR KR1020107006602A patent/KR20100059912A/ko not_active Withdrawn
- 2008-09-24 EP EP08835893A patent/EP2205279B1/de not_active Not-in-force
- 2008-09-24 MX MX2010003439A patent/MX2010003439A/es active IP Right Grant

Also Published As

Publication number	Publication date
PT2205279E (pt)	2011-07-11
JP2010540548A (ja)	2010-12-24
AU2008309059A1 (en)	2009-04-09
WO2009045796A1 (en)	2009-04-09
MX2010003439A (es)	2010-04-21
CA2697437A1 (en)	2009-04-09
DE602008006243D1 (de)	2011-05-26
KR20100059912A (ko)	2010-06-04
EP2205279B1 (de)	2011-04-13
EP2205279A1 (de)	2010-07-14
US20100247645A1 (en)	2010-09-30
RU2010116526A (ru)	2011-11-10
BRPI0817275A2 (pt)	2015-06-16
PL2205279T3 (pl)	2011-09-30
ES2364538T3 (es)	2011-09-06
CN101808665A (zh)	2010-08-18

Legal Events

Date

Code

Title

Description

2011-12-15

UEP

Publication of translation of european patent specification

Ref document number: 2205279

Country of ref document: EP

Publication	Publication Date	Title
ATE505203T1 (de)	2011-04-15	Pharmazeutische kombination aus aliskiren und valsartan
TN2010000135A1 (en)	2011-09-26	Galenical formulations of organic compounds
ECSP077999A (es)	2008-01-23	Formulaciones de una sal de bupropion de liberación modificada
CY1111470T1 (el)	2015-08-05	Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
ATE540680T1 (de)	2012-01-15	Pharmazeutische aripiprazol-zusammensetzungen
EP1635762A4 (de)	2011-07-06	Niedrigdosierte pharmazeutische pulver zur inhalation
JP2007527914A5 (de)	2008-04-10
IL183357A0 (en)	2007-09-20	Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
CO6440564A2 (es)	2012-05-15	Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
MX2009004017A (es)	2009-07-24	Usos de los compuestos carboxi-amido triazol y sus sales.
UA93709C2 (ru)	2011-03-10	12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CL2012003012A1 (es)	2014-02-21	Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
WO2008003050A3 (en)	2009-05-28	Gallium nitrate formulations
IL187632A (en)	2014-02-27	17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
AR054595A1 (es)	2007-06-27	Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
JO3239B1 (ar)	2018-03-08	تركيبات جالينية من مركبات عضوية
WO2005120518A3 (en)	2006-05-26	Use of atp analogues for treatment of cardiovascular diseases
AR067351A1 (es)	2009-10-07	Combinacion de picotamida con nafronil
MXPA05007253A (es)	2005-12-14	Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en)	2012-09-05	Galenical formulations of organic compounds
ZA201005394B (en)	2014-01-29	15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
WO2007071721A3 (en)	2007-09-07	Ginger extract for inhibiting human drug transporters
MX2011009846A (es)	2011-09-29	Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
TW200833375A (en)	2008-08-16	Pharmaceutical compositions